StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3085% above fair value
$286.00−2.84 (-0.98%)

Close on Nov 3, 2026Market cap $505.40BP/E 80.8Yield 2.33%

AbbVie Reported After-Tax Earnings — GAAP by Quarter

Reported After-Tax Earnings — GAAP ($M) ($M)

QuarterlyAnnual

AbbVie Reported After-Tax Earnings — GAAP: $3,613M in Q2 2026, up 285.2% from a year earlier.

Latest, Q2 2026
3,613
Period ended Jun 30, 2026
Change on a year earlier
+285.2%
938 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
16
Documents cited below

Where the Q2 2026 figure comes from

“|| As reported (GAAP) | $ | 4,278 | $ | 3,613 | $ | 2.03”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Non-GAAP Reconciliations.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReported After-Tax Earnings — GAAP ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20263,613+285.2%Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 2026695-46.0%Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20251,816-8,354.5%Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 2025186-88.1%Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025938-31.5%Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 20251,286-6.1%Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 2024-22-102.7%Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20241,561-12.2%Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20241,370-32.3%Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 20241,369+472.8%Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 2023822-66.8%Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 20231,778-55.0%Form 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20232,024–Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 2023239–Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20222,473–Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 20223,949–Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Reported After-Tax Earnings — GAAP ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap-gaap-aftertax

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?